Gary W Pace

Director Gary W Pace buys 30,000 shares of CRDF at $1.22; stock down 73.5% from 52-week high, now at $1.21

Gary W Pace, a Director of Cardiff Oncology, purchased 30,000 shares at $1.22 on 2026-06-18, bringing his holdings to 1.36M shares. The purchase occurs at a substantial discount to the 52-week high, with the stock trading at -73.5% from that peak and -31.2% over the past 30 days. His prior purchases at CRDF show mixed results: two early 2025 buys declined 14.3% over 30 days, while a December 2024 purchase rose 38.8% in the same window, and a December 2023 purchase ultimately gained 277.4% over 90 days. The company faces headwinds—annual revenue declined 13.2% and it is unprofitable with a $-12.3M net loss on $41.0K quarterly revenue. While Pace's cross-ticker track record shows a 66.67% 90-day win rate on buys and a 90d average return of +70.7%, his same-ticker history at CRDF is less consistent, with 3 of 5 prior buys achieving positive 90-day returns.

Director Gary Pace purchases 290,000 shares of CRDF at $2.45 for $710,500 total; stake grows 27.5% post-transaction to 1,345,676 shares.

Director Gary W. Pace executed 2 separate purchases totaling 290,000 shares for $710,500.00 on 2025-07-30, increasing his holdings from 1,055,676 shares to 1,345,676 shares—a 27.5% increase. His four prior buys at CRDF achieved a 100% win rate at the 90-day mark (ranging from +37.7% to +277.4%), and his cross-ticker buy track record shows an average 90d return of +109.1% with a 100.00% win rate. This transaction occurs as the stock trades at $2.37, down 55.7% from its 52-week high of $5.35 and down 32.5% over the last 30 days, though Cardiff Oncology reported revenue of $121,000.00 in its latest quarter and remains unprofitable with a net income of $-13.9M. The scale of the acquisition—nearly 290.0K shares—and the historical accuracy of Pace's prior timing decisions provide material context for investors monitoring director-level capital deployment during a period of significant price decline.

Director PACE GARY W purchases 361.6K shares at $2.60 for $940.2K, raising stake to 1.06M shares (+51.8%)

Director Gary W. Pace completed 2 separate purchases totaling 361,615 shares for $940,199.00 at $2.60 per share on 2024-12-11, expanding his holdings by 51.8% to 1,059,376 shares post-transaction. This represents a substantial accumulation by a senior company insider at a price point 44.7% below the stock's 52-week high. Notably, Pace's prior 2 trades at Cardiff Oncology were both well-timed, with 90-day returns of +277.4% and +83.7%, establishing a pattern of accumulation preceding significant appreciation at this ticker. The company remains unprofitable ($-11.9M net income in the latest full year) with minimal quarterly revenue ($165.0K), though it posted 26.4% annual revenue growth, suggesting the stock may remain volatile until the business achieves cash-flow sustainability.